Progression-free survival (PFS) and subgroups analyses of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs): updated results from the phase II TALENT trial (GETNE 1509)
Capdevila, J Fazio, N Lopez-Lopez, C Teule, A Valle, Juan W Tafuto, S Custodio, AB Reed, N Raderer, M Grande, E
Capdevila, J
Fazio, N
Lopez-Lopez, C
Teule, A
Valle, Juan W
Tafuto, S
Custodio, AB
Reed, N
Raderer, M
Grande, E
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Capdevila J, Fazio N, L�pez-L�pez C, Teule A, Valle JW, Tafuto S, et al. Progression-free survival (PFS) and subgroups analyses of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs): updated results from the phase II TALENT trial (GETNE 1509). J Clin Oncol. 2019;37(4_suppl):332-.